Issuu on Google+

Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020 The Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy GlobalData analysis finds that the prostate cancer therapeutics market in France is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Prostate-Cancer-France-Drug-Forecasts-and-Treatment-Analysis-to2020&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. The introduction of new therapies for metastatic prostate cancer is expected to expand the market further. In 2009, the France accounted for approximately 7% of the global prostate cancer therapeutics market. In 2009, leuprolide was the leading drug with approximate sales worth $50m and a market share of 24% of the prostate cancer therapeutics market in France. Taxotere was the most used therapy for hormone refractory patients and accounted for 20% of the total prostate cancer therapeutics market in France. The impact of generic competition for Casodex in 2008 and Taxotere in 2011 is expected to partially offset the growth in revenue due to new product launched in the forecast period 2009 to 2020. GlobalData, the industry analysis specialist, has released its new report, “Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020�. The report is an essential source of information and analysis on the French prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the French prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer


sector. It quantifies the unmet need in the French prostate cancer therapeutics market, highlighting the opportunity for future players. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--France-DrugForecasts-and-Treatment-Analysis-to2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782


Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020